𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues

✍ Scribed by Umeda, Tomoko; Eguchi, Yutaka; Okino, Kouji; Kodama, Masashi; Hattori, Takanori


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
774 KB
Volume
183
Category
Article
ISSN
0022-3417

No coin nor oath required. For personal study only.

✦ Synopsis


The plasminogen activation (PA) system may participate in cancer invasion and metastasis. A series of breast cancer tissue specimens was analysed using in situ hybridization and immunohistochemistry. Urokinase-type plasminogen activator (u-PA) mRNA was detected in cancer cells and fibroblasts adjacent to them and its expression was found to be more intense in invasive than in intraductal regions. In invasive but not in intraductal regions, especially those with abundant stroma, plasminogen activator inhibitor-1 (PAI-1) mRNA was observed in cancer cells, fibroblasts, macrophages, and endothelial cells, and PAI-2 mRNA was present in cancer cells, and fibroblasts, macrophages, and lymphocytes around them. These PAI-1-and PAI-2-positive cancer cells were localized at the periphery of the invasive front. Immunohistochemistry yielded basically similar results. A retrospective study of surgically resected breast cancers from 73 patients revealed significant clinical differences associated with u-PA and PAI-2 expression in cancer cells, associated with a poor and a good prognosis, respectively. These findings indicate that breast cancer cells and fibroblasts express u-PA initially and then its inhibitors, and that this process is related to invasion. Expression of u-PA and PAI-2 in cancer cells themselves may serve to up-regulate and limit PA-mediated invasion and metastasis, respectively.


πŸ“œ SIMILAR VOLUMES


Expression and cellular localization of
✍ Dubuisson, L.; Monvoisin, A.; Nielsen, B. S.; Le Bail, B.; Bioulac-Sage, P.; Ros πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 437 KB πŸ‘ 1 views

The urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play an important role in tumour invasion. Previous studies have shown by RT-PCR that uPA and uPAR mRNAs are expressed in human hepatocellular carcinoma (HCC). Here, in situ hybridization, immunohistochemistry, and double immunoΒ―

ELISA for complexes between urokinase-ty
✍ Hans de Witte; Helle Pappot; Nils BrΓΌnner; Jan GrΓΈndahl-Hansen; Gunilla HΓΈyer-Ha πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 131 KB πŸ‘ 1 views

A sandwich-type ELISA has been developed for the assessment of complexes between urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in extracts of squamous cell lung carcinomas. The assay is based on a combination of rabbit polyclonal anti-uPA antibodies and a biotinylated mouse anti

Novel inhibitors of urokinase-type plasm
✍ Kristina Cakarovski; Jenny Y. Leung; Christina Restall; Anna Carin-Carlson; Euni πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 339 KB πŸ‘ 1 views

## Abstract The plasminogen‐activating (PA) and matrix metalloproteinase (MMP) enzyme systems are implicated in proteolytic turnover of the extracellular matrix (ECM) associated with biologic processes including wound healing, inflammation and angiogenesis. Aberrant expression of components of the

Co-expression of urokinase-type plasmino
✍ Il-Kyoo Park; Bum-Joon Kim; Young-Joo Goh; Mi-Ae Lyu; Chung-Gyu Park; Eung-Soo H πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 205 KB πŸ‘ 1 views

The expression of urokinase-type plasminogen activator (u-PA), its receptor (u-PAR) and metalloproteases activity were analyzed in 4 human gastric-cancer cell lines (AGS, Hs746T, SNU-1, and SNU-5), in an attempt to relate these activities to their invasive potential and tumorigenicity on the modifie

ELISA for complexes of urokinase-type an
✍ Nicolai Grebenschikov; Fred Sweep; Anneke Geurts; Peter Andreasen; Hans De Witte πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 125 KB πŸ‘ 1 views

An ELISA has been developed for the assessment of complexes between the urokinase-type (uPA) and the tissuetype plasminogen (tPA) activators with their inhibitor type-1 (PAI-1) in cell-culture medium and cytosolic extracts of breast tumours. The ''4-stage/2-site'' ELISA involves 2 polyclonal antibod